Non-Hodgkin Lymphoma | Specialty

The non-hodgkin lymphoma condition center is a comprehensive resource for clinical news and expert insights on non-hodgkin lymphoma. Read more at OncLive.

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

June 15th 2025

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL

June 15th 2025

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

June 14th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma

June 13th 2025

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

FDA Approves Tablet Formulation of Zanubrutinib for B-Cell Malignancies

June 11th 2025

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Collaborating With Dermatologists: Coordinating Skin-Directed Therapy and Follow-Up in CTCL

June 10th 2025

Panelists discuss how multidisciplinary collaboration between dermatologists and oncologists helps optimize personalized treatment plans by integrating skin-directed and systemic therapies.

Managing Early-Stage Mycosis Fungoides: Treatment Goals and Topical Therapy Selection

June 10th 2025

Panelists discuss how therapeutic goals for early-stage CTCL focus on symptom control with skin-directed therapies, avoiding systemic chemotherapy due to long-term toxicity and poor outcomes.

Bispecific Antibodies Improve TTNT and Reshape R/R Follicular Lymphoma Management

June 5th 2025

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

Understanding CTCL Staging: From Limited Mycosis Fungoides to Advanced Disease

June 4th 2025

Panelists discuss how early-stage CTCL is defined using TNMB staging criteria, the typical presentation of patients at various stages, and the implications for treatment approaches.

Cutaneous T-Cell Lymphoma Insights: Distinguishing MF and SS, and Recognizing Early-Stage Clues

June 4th 2025

Panelists discuss how CTCL is diagnosed, distinguished between Mycosis Fungoides and Sézary Syndrome, and why early-stage disease is often misdiagnosed due to its resemblance to benign skin conditions.

Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL

June 1st 2025

Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.

Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma

June 1st 2025

Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.

Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL

May 31st 2025

Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma

May 30th 2025

Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.

ctDNA-Based MRD Provides Prognostic Value for First-Line Treatment in DLBCL

May 30th 2025

PhasED-Seq–assessed ctDNA-based MRD negativity was strongly associated with improved PFS after frontline treatment in patients with DLBCL.

Fixed-Duration Bispecific Antibodies Are Effective, Safe, and Convenient for Follicular Lymphoma

May 29th 2025

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.